Synthetic analog · 9 amino acids · 1,206.5 Da

Nonapeptide-1 studies and research data

PepBank has 3 nonapeptide-1 studies with results. 1 of them gave nonapeptide-1, with 8 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 8 results and 6 papers. Newer studies from Europe PMC

Results in people

0% of 8 results

Results in animals

0% of 8 results

Results in lab cells

100% of 8 results

From computer models

0% of 8 results

The molecule

Nonapeptide-1 identity

Identifiers, parent molecule, targets and development stage, from curated data.

Nonapeptide-1 is a modified nonapeptide also called Melanostatine-5. It differs from alpha-MSH and from sh-nonapeptide-1. Its cosmetic use and carrier formulations do not establish an isolated treatment for pigmentary disease.

Kind: Synthetic analog · 9 residues
Identifiers: PubChem CID10418849 (opens in a new tab)UNII64W45420K5 (opens in a new tab)CAS158563-45-2
Parent: Analog of Alpha-melanocyte-stimulating hormone (POMC-derived) · residues 142-150PMID 10447099 identifies the alpha-MSH(5-13) analog. UniProt places mature alpha-MSH at 138-150.
Development: UnknownClinicalTrials.gov returned zero records for the three product names. No trial IDs or trials that tested participants were established. The melasma publication tests a combination, not this product alone. A formal development phase and developer remain unestablished. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Melanocortin 1 receptorMC1R	Antagonist	Not statedSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

9 amino acids · 3 modifications

H-

MPRFKPV

Alignment to Alpha-melanocyte-stimulating hormone (POMC-derived)

Calculated from the two sequences. Curated notes are shown as given.

4 of 9 aligned residues identical (44%) · 3 substitutions · 2 non-canonical residues · 1 modified residue · Alpha-melanocyte-stimulating hormone (POMC-derived) 5–13

Top row: Alpha-melanocyte-stimulating hormone (POMC-derived) (parent)
Bottom row: Nonapeptide-1

Same as parent
Substituted
Non-canonical or D-form
Added
Gap
Modified side chain or end
Parent context

Differences from the parent

1Parent 5 · analog 1Glu → Met · SubstitutionPosition 1 in the nine-residue analog.
2Parent 6 · analog 2His → Pro · Substitution
3Parent 7 · analog 3Phe → D-Phe · D-amino acidD-phenylalanine at residue 3.
4Parent 9 · analog 5Trp → D-Trp · D-amino acidD-tryptophan at residue 5.
5Parent 10 · analog 6Gly → Phe · Substitution
6Parent 13 · analog 9Val, modified · C-terminal amideC-terminal carboxamide.

Basis: PMID 10447099 identifies the alpha-MSH(5-13) analog. UniProt places mature alpha-MSH at 138-150.

Calculated from the two sequences with @pepdb/chem alignToParent (ungapped unless a gap scores higher). The record’s curated notes are shown as given.

Properties

From identity sources

Formula: C₆₁H₈₇N₁₅O₉S
Molecular weight: 1,206.5 g/mol
Monoisotopic mass: 1,205.6532 Da

PubChem CID 10418849(opens in a new tab)retrieved 2026-10-27
FDA GSRS 64W45420K5(opens in a new tab)retrieved 2026-10-27

Calculated from the sequence

pKa set

Average mass: 1,206.52 Da; Sum of ExPASy residue masses + water + C-amide · ExPASy Compute pI/Mw; FindMod
Monoisotopic mass: 1,205.6532 Da; Sum of ExPASy residue masses + water + C-amide · ExPASy FindMod
Isoelectric point (pI): Not calculated; The net charge does not reach zero between pH 0 and 14 (the peptide has no acidic or no basic group in this model).
Net charge at pH 7.4: 2.94; Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
GRAVY (hydropathy): −0.089; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 5,500 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
Instability index: 139.08; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; Above 40: classed as possibly unstable (ExPASy).
Aliphatic index: 32.2; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 0.64 kcal/mol; Mean solubility value (negated) · Boman 2003; 2.48 or below: lower protein-binding potential (Boman).
Hydrophobic moment (μH): Not calculated; The sequence is too short for this method.

D-amino acids have the same mass and charge as L forms. Hydrophobicity scales were measured on L forms.
Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

Net charge at pH 7.4: 2.94

Point or use arrow keys

Henderson-Hasselbalch, EMBOSS pKa set, C-amide. Calculated, not measured.

Show as table

pH	Net charge
0	3.00
1	3.00
2	3.00
3	3.00
4	3.00
5	3.00
6	3.00
7	2.98
8	2.80
9	2.27
10	1.90
11	1.36
12	0.82
13	0.25
14	0.03

Composition

Hydrophobic22% (2)M V
Aromatic33% (3)F W
Positive22% (2)K R
Special22% (2)P

9 residues. Each residue counts in one class; F and W count as aromatic.

A Ala0 · 0%

I Ile0 · 0%

L Leu0 · 0%

M Met1 · 11%

V Val1 · 11%

F Phe2 · 22%

W Trp1 · 11%

Y Tyr0 · 0%

H His0 · 0%

K Lys1 · 11%

R Arg1 · 11%

D Asp0 · 0%

E Glu0 · 0%

N Asn0 · 0%

Q Gln0 · 0%

S Ser0 · 0%

T Thr0 · 0%

C Cys0 · 0%

G Gly0 · 0%

P Pro2 · 22%

3D structure

PredictedAlphaFold DB · P01189

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

2D structure

Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).

SMILES fromPubChem CID 10418849(opens in a new tab)

CC(C)[C@@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCSC)N

Results by area

Nonapeptide-1 results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

3 of 6 studies have results (50%), published 1999 to 2024. Top row: every study. Bottom row: studies with results about Nonapeptide-1, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies6 in all, 1996 to 2024

Studies with results3 in all, 1999 to 2024

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Nonapeptide-1 studies on receptors and cell signals

8 results · people 0 · animals 0 · lab 8

Top 3 of 8 results

In cells, 153N-6 inhibited native alpha-MSH action at the MC1 receptor.Peptides, 1999
In cells, 153N-6 inhibited the synthetic agonist [Nle4,D-Phe7]alpha-MSH at the MC1 receptor.Peptides, 1999
In cells, the Ki of 153N-6 was 9.0 X 10(-6) M.Peptides, 1999

Trials and papers

Nonapeptide-1 trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

0 trials match. Highest phase first. Data from ClinicalTrials.gov.

No trial matches these filters.

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

6 studies match. Retracted studies are left out.

Showing 4 of 6 studiesquery qry_9ab5090df8e8d30020c788a2

Studies with results

3 studies

Not a test of Nonapeptide-1 alone · 2024

5 results

Enhanced skin benefits of EGCG loaded in nonapeptide-1-conjugated mesoporous silica nanoparticles to reverse skin photoaging.

Huang et al. 2024International journal of pharmaceuticscited by 6

PMID 39260749DOI 10.1016/j.ijpharm.2024.124690PUB-39260749

Full text at the publisher5 results where Nonapeptide-1 was a tool, carrier or part of a combination

Publisher page See results (5)

In vitro (cells) · mouse · 1999

8 results

Synthesis of 153N-6 analogues and structure-function analysis at murine melanocortin-1 (MC1) receptors.

Sahm et al. 1999Peptidescited by 5

PMID 10447099DOI 10.1016/s0196-9781(99)00047-9PUB-10447099

Full text at the publisher8 results where Nonapeptide-1 was given

Publisher page See results (8)

Not a test of Nonapeptide-1 alone · 2021

3 results

A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance.

Chatterjee et al. 2021Indian journal of dermatology, venereology and leprologycited by 2

PMID 34379946DOI 10.25259/ijdvl_976_18PUB-34379946

Full text at the publisher3 results where Nonapeptide-1 was a tool, carrier or part of a combination

Publisher page See results (3)

More studies

1 study

PubMed tag: none · 1997

Characterization of the binding of MSH-B, HB-228, GHRP-6 and 153N-6 to the human melanocortin receptor subtypes.

Schiöth et al. 1997Neuropeptidescited by 29

PMID 9574823DOI 10.1016/s0143-4179(97)90002-0PUB-09574823

Full text at the publisher

Publisher page

No result for Nonapeptide-1 (2 studies on this page)

These studies name Nonapeptide-1 but give no result for it (for example, the results concern another peptide in the study).

Indexing hint: Animal study · 1996

Characterization of a putative alpha-MSH antagonist 153N-6 at melanocortin receptor subtypes by radioligand binding.

Chhajlani et al. 1996Peptidescited by 10

PMID 8801544DOI 10.1016/0196-9781(95)02130-2PUB-08801544

Full text at the publisher

Publisher page

PubMed tag: none · 2022

Effects of tea polyphenols on UVA-induced melanogenesis via inhibition of α-MSH-MC1R signalling pathway.

Chen et al. 2022Postepy dermatologii i alergologiicited by 5

PMID 35645678PMC9131962DOI 10.5114/ada.2022.115890PUB-35645678

Free to read · publisher termsCC BY-NC

Read at source

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Nonapeptide-1 studies: 3 papers with results

Page 1 of 1

Synthesis of 153N-6 analogues and structure-function analysis at murine melanocortin-1 (MC1) receptors.
Sahm UG · Peptides · 1999
In vitro (cells) · mouse · 8 results
Enhanced skin benefits of EGCG loaded in nonapeptide-1-conjugated mesoporous silica nanoparticles to reverse skin photoaging.
Huang ZJ · International journal of pharmaceutics · 2024
Not a test of Nonapeptide-1 alone · 5 results
A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance.
Chatterjee M · Indian journal of dermatology, venereology and leprology · 2021
Not a test of Nonapeptide-1 alone · 3 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	FDA lists a substance identity record. A UNII does not establish regulatory approval. No approved therapeutic product was established.	27 Oct 2026	precision.fda.gov (opens in a new tab)
EU	EMA	No EMA medicinal authorisation was established by the searches. The CosIng ingredient reference does not establish medicinal approval.	27 Oct 2026	ec.europa.eu (opens in a new tab)
Sport	WADA	Status unknown Nonapeptide-1 is not named in the 2026 list.	2026 List	wada-ama.org (opens in a new tab)
European Union	Note	INCI: NONAPEPTIDE-1. CosIng reference 57418. Secondary ingredient dictionaries report this entry. The official page did not return the ingredient detail during this check. An inventory entry is not a medicinal approval.	27 Oct 2026	specialchem.com (opens in a new tab)

Safety outcomes

Reported effects from study results.

No safety results from studies in people

The studies with results report no safety outcomes for this peptide. That does not mean it is safe.

Doses studied

The doses that these studies used. They are not recommendations.

No dose was reported in the study results.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000151
Peptide version: 2
Peptide hash: 6a900c54276cce60…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 287300
27 Oct 2026CreatedData version 256739

For developers

curl -s https://pepbank.io/v1/briefs/nonapeptide-1

Evidence summary for Nonapeptide-1: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Nonapeptide-1 studies and research data

Nonapeptide-1 identity

Targets

Sequence and structure

Sequence

Alignment to Alpha-melanocyte-stimulating hormone (POMC-derived)

Properties

Net charge by pH

Composition

3D structure

2D structure

Nonapeptide-1 results by year and outcome

What the studies measured

Nonapeptide-1 studies on receptors and cell signals

Nonapeptide-1 trials

Papers

Studies with results

Enhanced skin benefits of EGCG loaded in nonapeptide-1-conjugated mesoporous silica nanoparticles to reverse skin photoaging.

Synthesis of 153N-6 analogues and structure-function analysis at murine melanocortin-1 (MC1) receptors.

A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance.

More studies

Characterization of the binding of MSH-B, HB-228, GHRP-6 and 153N-6 to the human melanocortin receptor subtypes.

Characterization of a putative alpha-MSH antagonist 153N-6 at melanocortin receptor subtypes by radioligand binding.

Effects of tea polyphenols on UVA-induced melanogenesis via inhibition of α-MSH-MC1R signalling pathway.

Newer studies

Nonapeptide-1 studies: 3 papers with results

Regulatory and safety

Doses studied

Data and API

Peptide

Latest changes

For developers

Related peptides

Nonapeptide-1 results by year and outcome

Nonapeptide-1 studies on receptors and cell signals

Nonapeptide-1 trials

Papers

Studies with results

Enhanced skin benefits of EGCG loaded in nonapeptide-1-conjugated mesoporous silica nanoparticles to reverse skin photoaging.

Synthesis of 153N-6 analogues and structure-function analysis at murine melanocortin-1 (MC1) receptors.

A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance.

More studies

Characterization of the binding of MSH-B, HB-228, GHRP-6 and 153N-6 to the human melanocortin receptor subtypes.

Characterization of a putative alpha-MSH antagonist 153N-6 at melanocortin receptor subtypes by radioligand binding.

Effects of tea polyphenols on UVA-induced melanogenesis via inhibition of α-MSH-MC1R signalling pathway.

Nonapeptide-1 studies: 3 papers with results

Regulatory and safety

Doses studied

Data and API

Peptide

Latest changes

For developers